Matan Companies breaks ground on Progress Labs at Riverside I The City-based project will feature 215,000 square feet of biomanufacturing-ready space — including a 96,000 square foot existing building, which is available for immediate occupancy, as well as a 118,000 square foot expansion building, which will be delivered in June 2022.
ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
Image: https://www.americangene.com
The extension follows a tumultuous time for the Gaithersburg company, making it unclear if the government would proceed with deals as normal.
The German firm hopes to expand its cancer treatments with the purchase.
Image: BioNTech is buying a Gaithersburg manufacturing facility on Clopper Road from Kite Pharma. GOOGLE STREET VIEW
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that its’ academic collaborator, Dr. John Sampson of Duke University’s Department of Neurosurgery, has been recognized as a World Expert in Glioblastoma by Expertscape, an online resource that identifies the world’s top experts in all medical fields. The publication recognized the top 0.1% of scholars writing about glioblastoma over the past ten years, a level they label as “World Expert”. Dr. Sampson’s recognition as a World Expert in glioblastoma is part of Glioblastoma Awareness Day, which is being celebrated today, Wednesday, July 21, 2021.
MAINZ, Germany & SANTA MONICA, Calif.–(BUSINESS WIRE)–BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.
Image: https://biobuzz.io
Montgomery County is set to consider plans for the first phase of a five-building life sciences project in Rockville.
An affiliate of life sciences giant Alexandria Real Estate Equities filed plans for a 200K SF research and development building as part of an 18-acre project on Darnestown Road. The Montgomery County Planning Board is scheduled to hear the plans on July 29.
Image: Montgomery County Planning Department A rendering of the 200K SF lab building on Darnestown Road in Rockville.
The biomedical research ecosystem has delivered advances that not long ago would have been inconceivable, exemplified by highly effective COVID-19 vaccines developed by global partners and approved in less than a year. The United States stands at a moment of unprecedented scientific promise and is challenged to ask: What more can we do to accelerate the pace of break-throughs to transform medicine and health? Toward that end, President Biden recently proposed to create a new entity, the Advanced Research Projects Agency for Health (ARPA-H), within the National Institutes of Health (NIH) “to develop breakthroughs—to prevent, detect, and treat diseases like Alzheimer’s, diabetes, and cancer,” requesting $6.5 billion in the fiscal year 2022 budget.
Come join the Virginia Tech Corporate Research Center for Game Changer Week! Game Changer Week, set for August 23-27, 2021 will bring together industry disruptors, entrepreneurs, innovators, and researchers for a variety of online and in-person events. Events include webinars, happy hours, start-up mentoring, special guests, open houses, and more!
SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of National Institutes of Health, under which they will collaborate on the non-clinical and clinical development of Ascentage Pharma’s drug compound pelcitoclax.
